ECCO 2023

S1P modulators - a rising class of drugs

A focus on surgery and post-operative maintenance

JAK inhibitors - small molecules to treat IBD

New molecules on the horizon!

Prolonged treatment with Ozanimod recaptures remission in about 1/3 of UC patients not responding at week 10

Long-term extension of ustekinumab in UC

Long-term duration of response with ozanimod in UC

Upadacitinib works in bionaive and bio-exposed pts in CD and UC

Upadacitinib for fistulizing Crohn´s disease?

Mucosal healing induced by vedolizumab in chronic pouchitis

No impact of previous therapies for Upadacitinib in Crohn's disease

Latest update on JAK inhibition

S1P modulators in UC

Upadacitinib is efficacious for UC regardless of biologic pretreatment

Vedolizumab heals pouch mucosa

Medium-term outcome of IBD patients diagnosed at preclinical stage

Update zu JAK-Inhibitoren bei CED

Η μεσοπρόθεσμη έκβαση ασθενών με ΙΦΝΕ που διαγιγνώσκονται σε προκλινικό στάδιο

S1P-Modulatoren bei Colitis ulcerosa

Lang Termijn respons met ozanimod bij colitis ulcerosa

Upadacitinib: Vortherapien spielen keine Rolle mehr bei Morbus Crohn

Upadacitinib is efficient bij colitis ulcerosa, ongeacht eerdere blootstelling aan biologische therapieen

Il prolungamento del trattamento con Ozanimod induce remissione clinica in circa 1/3 dei pazienti trattati e che non hanno mostrato risposta clinica entro le prime 10 settimane

Studio lungo termine di ustekinumab in UC

New aspects on safety of anti-TNF treatment

Anti-IL23 drugs: is it all the same?

Safety update on JAKis - new worries?

S1P-modulators: a spotlight on safety

Ozanimod shows good efficacy and safety profile in UC patients after 2 and 3 years of treatment

Positive effects of Upadacitinib on resolution of abdominal symptoms and normalization of fatigue in active UC pts

Risk of IBD from early antibiotic exposure in live

Etrasimod shows fast stool frequency and rectal bleeding normalization in UC patients

Ileostomy with better prognosis than pouch in PSC

Ozanimod shows good efficacy and safety profile after 2&3 years of treatment

Les antibiotiques dans la petite enfance augmentent le risque de maladie de Crohn pédiatrique

Το upadacitinib επιφέρει ύφεση των κοιλιακών συμπτωμάτων και αποκατάσταση της χρόνιας κόπωσης σε ασθενείς με ενεργό ελκώδη κολίτιδα

Ileostomie mit besserer Prognose als Pouch bei PSC

Rapido controllo del sanguinamento rettale e della frequenza evacuativa in pazienti affetti da RCU trattati con Etrasimod

10 years of Tofacitinib – still more lessons to learn

Practice-changing data on surgery in CD and UC

Postoperative recurrence in CD

Vedolizumab for preventing postoperative reccurence of CD

Enteral nutrition - food for thought!

Surgery in CD - resetting or not?

Timing of surgery in Crohn's disease

Biologics in CD – is earlier better?

Peri- and postoperative management of CD

Epigenetic fingerprinting - a novel tool for precision medicine in IBD

DNA methylation predicts response to biologics in IBD

Is it feasible to stop anti-TNF treatment in combinational therapies in IBD?

New drugs on the block!

Ileocaecal Crohn's disease - should we call the surgeon first?

Surgical and post-operative management in CD

Another clue for the role of the microbiome in PSC?

Early treatment with biologics in IBD

Vedolizumab prevents postoperative recurrence in CD

Post-surgical Crohn's disease

Another clue for the role of the microbiome in PSC?

Biosimilars

Biologics in CD - is earlier better?

Résection chirurgicale au course de la maladie de Crohn: une remise a zéro ou pas?

Postać ileocekalna choroby Crohna - czy chirurgia ma pierwszeństwo?

Vedolizumab en prévention de la récidive postopératoire de la MC

Chirurgischer Verlauf nach Morbus Crohn

Vedolizumab previene la recidiva post operatoria nei pazienti con malattia di Crohn

Aanpak van de (post)operatieve Crohn patient

Neue Substanzen!

Peri- und postoperatives Management bei Morbus Crohn

Epigenetic Fingerprinting - ein neues Werkzeug für die Präzisionsmedizin bei CED

Résection chirurgicale précoce dans la MC

Είναι ευχερές να διακόψουμε τους αντι-TNF παράγοντες από τη συνδυασμένη θεραπείας τους με κλασικά ανοσοκατασταλτικά

Comprehensive remission - the new standard!?

Histology - a new therapeutic target in UC?

Disease clearance induced by etrasimod in UC

Comprehensive Disease Control

Comprehensive Disease Control

New ECCO guidelines on extraintestinal manifestations in IBD

New opportunities from the application of artificial intelligence (AI) to the new endoscopic technologies

Our patients will be better off in the near future!

Mucosal signatures suggest a mechanism for early CD postoperative recurrence

GPX4 fueling postoperative recurrence in Crohn's disease

Comprehensive overview of surgery in IBD

Sequencing in IBD - congress overview

Panoramica completa sulla chirurgia nelle malattie infiammatorie cronicale intestinali

Nowe wytyczne ECCO dotyczące manifestacji pozajelitowych w IBD

Una vida mejor en el futuro inmediato para nuestros pacientes

GPX4 fördert postoperatives Morbus Crohn Rezidiv

Mucosal signatures suggest a mechanism for early CD postoperative recurrence

Nuove opportunità dall’applicazione dell’intelligenza artificiale alle nuove tecniche endoscopiche

Sequencing nelle malattie infiammatorie cronicale intestinali